Stevens Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Stevens Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-14,761	Closed	-$1.76M	–	835
2019 Q1	$1.76M	Buy	14,761 +12,297	+499%	+$1.58M	0.08%	291
2018 Q4	$269K	Buy	+2,464	New	+$308K	0.01%	583
2018 Q3	–	Sell	-6,364	Closed	-$841K	–	940
2018 Q2	$841K	Buy	6,364 +909	+17%	+$85.7K	0.03%	463
2018 Q1	$404K	Buy	+5,455	New	+$364K	0.02%	560
2014 Q3	–	Sell	-7,076	Closed	-$211K	–	1229
2014 Q2	$211K	Buy	+7,076	New	+$224K	0.01%	917

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stevens Capital Management's SRPT Position: Q2 2019 in Review

Stevens Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2019, closing a stake of 14,761 shares — an estimated $1.76M sold.

Stevens Capital Management first reported a position in SRPT in Q2 2014 and held it in 5 quarters. The position peaked at $1.76M in Q1 2019. 365 funds tracked by Wall St. Rank hold SRPT as of Q2 2019.

Stevens Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2019 after selling out during the quarter.
Stevens Capital Management sold 14,761 Sarepta Therapeutics shares in Q2 2019, an estimated $1.76M.
Stevens Capital Management first reported a position in Sarepta Therapeutics in Q2 2014 and held it in 5 quarters.
Stevens Capital Management's Sarepta Therapeutics position peaked at $1.76M in Q1 2019.
365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2019.

Based on Stevens Capital Management's 13F filing for Q2 2019, filed 31 Jul 2019.